Trial 6G-11-2

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma.

Type: Cancer Therapy
Phase: Phase III
Status: Open to Accrual
Treatments: Vaccine
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Rose Lai, M.D.
Other Trial Staff:

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.